These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7351114)

  • 1. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.
    Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
    Clin Pharmacol Ther; 1980 Jan; 27(1):22-31. PubMed ID: 7351114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presystemic and systemic glucuronidation of propranolol.
    Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
    Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propranolol glucuronide cumulation during long-term propranolol therapy: a proposed storage mechanism for propranolol.
    Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
    Clin Pharmacol Ther; 1979 Dec; 26(6):686-95. PubMed ID: 498710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.
    Schneck DW; Pritchard JF; Gibson TP; Vary JE; Hayes AH
    Clin Pharmacol Ther; 1980 Jun; 27(6):744-55. PubMed ID: 7379441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of (+) and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (+/-)-propranolol in man.
    Von Bahr C; Hermansson J; Tawara K
    Br J Clin Pharmacol; 1982 Jul; 14(1):79-82. PubMed ID: 7104170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma concentrations of propranolol and 4-hydroxypropranolol during chronic oral propranolol therapy.
    Wong L; Nation RL; Chiou WL; Mehta PK
    Br J Clin Pharmacol; 1979 Aug; 8(2):163-7. PubMed ID: 486291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade.
    Wilson TW; Firor WB; Johnson GE; Holmes GI; Tsianco MC; Huber PB; Davies RO
    Clin Pharmacol Ther; 1982 Dec; 32(6):676-85. PubMed ID: 7140133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etintidine-propranolol interaction study in humans.
    Huang SM; Weintraub HS; Marriott TB; Marinan B; Abels R
    J Pharmacokinet Biopharm; 1987 Dec; 15(6):557-68. PubMed ID: 2897462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic and clinical observations in cyanotic children on propranolol therapy.
    Riopel DA; Walle T
    Clin Pharmacol Ther; 1980 Dec; 28(6):743-50. PubMed ID: 7438690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verapamil kinetics in normal subjects and patients with coronary artery spasm.
    Freedman SB; Richmond DR; Ashley JJ; Kelly DT
    Clin Pharmacol Ther; 1981 Nov; 30(5):644-52. PubMed ID: 7297023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereoselective ring oxidation of propranolol in man.
    Walle T; Walle UK; Wilson MJ; Fagan TC; Gaffney TE
    Br J Clin Pharmacol; 1984 Nov; 18(5):741-8. PubMed ID: 6508983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
    Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
    J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cholestyramine and colestipol on the plasma concentrations of propranolol.
    Hibbard DM; Peters JR; Hunninghake DB
    Br J Clin Pharmacol; 1984 Sep; 18(3):337-42. PubMed ID: 6487473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies of the absorption and removal of propranolol in hypertensive patients during therapy.
    Chidsey CA; Morselli P; Bianchetti G; Morganti A; Leonetti G; Zanchetti A
    Circulation; 1975 Aug; 52(2):313-8. PubMed ID: 1149212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of ageing on the hepatic clearance of propranolol.
    Castleden CM; George CF
    Br J Clin Pharmacol; 1979 Jan; 7(1):49-54. PubMed ID: 760742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicokinetics of deltamethrin and its 4'-HO-metabolite in the rat.
    Anadón A; Martinez-Larrañaga MR; Fernandez-Cruz ML; Diaz MJ; Fernandez MC; Martinez MA
    Toxicol Appl Pharmacol; 1996 Nov; 141(1):8-16. PubMed ID: 8917670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of food on the intravenous and oral dose kinetics of propranolol in the dog.
    Bai SA; Walle UK; Walle T
    J Pharmacokinet Biopharm; 1985 Jun; 13(3):229-41. PubMed ID: 4087163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic propranolol administration during pregnancy. Maternal pharmacokinetics.
    Smith MT; Livingstone I; Eadie MJ; Hooper WD; Triggs EJ
    Eur J Clin Pharmacol; 1983; 25(4):481-90. PubMed ID: 6653642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propranolol plasma levels and relief of migraine. Relationship between plasma propranolol and 4-hydroxypropranolol concentrations and clinical effects.
    Cortelli P; Sacquegna T; Albani F; Baldrati A; D'Alessandro R; Baruzzi A; Lugaresi E
    Arch Neurol; 1985 Jan; 42(1):46-8. PubMed ID: 3966884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of propranolol in the dog.
    Tse FL; Sanders TM; Reo JP
    Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.